###### Strengths and limitations of this study

-   This study is the first to review economic evaluation studies on clinical pharmacy services in China by using a formal systematic review approach.

-   This study was based on an evidence-based methodology to provide evidence to healthcare decision makers regarding the economic value of clinical pharmacy services, and it provides some suggestions and references for designing future economic evaluations of pharmacy interventions in the region.

-   The possible risk of bias in the included studies was assessed using the American College of Clinical Pharmacy checklist that was designed specifically to grade the quality of economic methods, the Cochrane Collaboration Methodology or the Newcastle-Ottawa Scale.

-   However, the heterogeneity among the included trials was relatively high, so we analysed the results qualitatively.

Introduction {#s1}
============

The concept and practice of clinical pharmacy services (CPS) originated in the USA.[@R1] The American College of Clinical Pharmacy's (ACCP) definition of clinical pharmacy refers to the contribution that pharmacists make in applying their professional knowledge to ensure high-quality rational drug therapy to produce optimal patient outcomes.[@R2] The published literature suggests that CPS could improve patient clinical outcomes, as pharmacists use their skills and knowledge to make the best use of medications in order to ensure safe and effective pharmacotherapy.[@R3] Pharmacist participation in physician rounds and provision of medication guidance can reduce the frequency of adverse drug events (ADEs) and medication errors and improve medication adherence.[@R5] In addition to clinical benefits, patients' physical, emotional, functional and social well-being have also been positively affected when measured using health-related quality-of-life assessments.[@R6]

In 2009, wide-ranging reforms of the healthcare system were announced in China. Hospitals account for approximately three-quarters of pharmaceutical sales in China. To compensate for diminishing state contributions, hospitals were permitted to charge a mark-up of up to 15% on medicines. The mark-up has had serious consequences. Doctors' salaries and bonuses were linked to drug sales, spurring excessive and inappropriate prescriptions.[@R7] In 2009, this system of mark-ups was abolished, and billions of yuan were poured into the public system, which aimed to control China's increasing health expenditure to provide affordable healthcare.[@R7] However, healthcare costs have continued to rise in China, which means that healthcare institutions need to identify and adopt efficient ways to control these costs. Although CPS have been developed in China and play an important role in improving patients' clinical outcomes, faced with limited resources and skyrocketing healthcare costs, healthcare policy-makers haven grown increasingly focused on the economic effectiveness and cost of services.

Economic evaluations play an important role in informing resource allocation decision and lead to the provision of information to public policy-makers and healthcare payers about the good value for the invested money afforded by a healthcare programme.[@R8] Published evidence of the economic value of CPS is an important resource, which can be used to justify pharmacist-led programmes and can also improve net revenue by reducing medical expenses. Beyond that, economic evaluations can also help improve the quality of CPS by guiding the choice of the most effective and cost-effective pharmacy programmes.[@R9]

China became interested in CPS as early as 1962; however, due to the economic and political climate, CPS were finally developed in the 21st century. While still in the early stages of development, CPS are becoming firmly established with the support of China's Ministry of Health (MoH) of the People's Republic of China.[@R12] In 2011, the MoH issued a policy that all secondary and tertiary hospitals should have at least three and five full-time clinical pharmacists, respectively. Furthermore, pharmacists needed to be trained in infectious diseases to be able to give guidance and approval for restricted antimicrobial use.[@R13] In 2018, the MoH indicated that pharmacists have the ultimate responsibility for prescription review.[@R14] The role of the pharmacist is becoming increasingly important, but whether and how to 'pay pharmacists for patient care' is still an area of debate.

In China, many significant original studies have been published about the measurement of the economic impact of CPS. To date, no study has reviewed economic evaluation studies on CPS in China using a formal systematic review approach. The objective of this study was to review these studies, to identify the types of CPS and the possible economic effects of these services in China, and to provide evidence of the economic value of CPS to healthcare decision makers. Additionally, this study provides some suggestions and references for designing future economic evaluations of pharmacy interventions in the region.

Method {#s2}
======

This study was largely based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting systematic reviews.[@R15] The PRISMA checklist is shown in the [online supplementary file](#SP1 SP2){ref-type="supplementary-material"}.
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Inclusion criteria {#s2-1}
------------------

### Participants {#s2-1-1}

Any patient group and the associated prescriptions were included.

### Intervention {#s2-1-2}

All CPS performed by a pharmacist or team of pharmacists were considered interventions. In this review, the term intervention conforms to the unabridged ACCP definition of a clinical pharmaceutical intervention, in which pharmacists provide patient care that optimises medication therapy and disease prevention and promotes health.[@R2]

### Outcomes {#s2-1-3}

The primary outcome was a full or partial economic assessment of the cost to provide a service. A full economic evaluation was conducted using four techniques: cost-minimisation analysis, cost-effectiveness analysis, cost-utility analysis and cost--benefit analysis. Partial economic evaluations were considered in terms of costs and consequences.[@R16]

### Study design {#s2-1-4}

Randomised controlled trials, semirandomised controlled trials, non-randomised controlled trials, cohort studies and before-and-after studies were included.

### Setting {#s2-1-5}

The research sites were in China.

### Language {#s2-1-6}

The articles were published in English or Chinese.

### Exclusion criteria {#s2-1-7}

Studies were excluded that evaluated only humanistic or clinical outcomes without an economic assessment; studies published in abstract form only or unoriginal work (letters or reviews) were also excluded. When full texts of the studies were unavailable, they were also excluded, and repeated publications were excluded.

Search strategy {#s2-2}
---------------

Relevant studies were identified by electronically searching the following databases: English databases (PubMed, Embase, the Cochrane Library, National Health Service Economic Evaluation Database), Chinese databases (China National Knowledge Infrastructure, WanFang Database, Chinese Biomedical Literature Database, VIP Database for Chinese Technical Periodicals) and search engines (Google Scholar and Bai Du Scholar). Articles were retrieved from the date of the inception of the database to 24 December 2017. In addition, the bibliographies of relevant identified articles were manually searched. The search terms combined the Medical Subject Headings (MeSH) headings with free-text words, including 'clinical pharmacy', 'pharmaceutical services', 'pharmaceutical care', 'pharmacy service', 'pharmacist', 'economic evaluation', 'cost-utility analysis', 'cost--benefit analysis' and 'cost-effectiveness analysis'. More details about the search strategy can be found in the attachment (shown in [online supplementary file](#SP1 SP2){ref-type="supplementary-material"}).

Study selection and data extraction {#s2-3}
-----------------------------------

Two study investigators independently screened and crosschecked all articles and extracted the data. In instances of disagreement, two reviewers resolved their differences of opinion by discussion to reach a consensus or consulted a third independent investigator to reach a consensus. Study selection was based on titles and abstracts, and the full texts were read after excluding obviously unrelated studies to make the ultimate decision regarding whether the study would be included. The extracted data included: the study design, setting, population, sample size, type of intervention, type of economic evaluation and economic outcomes.

Study appraisal and analysis {#s2-4}
----------------------------

The assessment of study quality was performed with the checklist from the ACCP that was designed specifically to grade the quality of the economic methods used, which included three assessment items: (1) the description of the comparator group used; (2) the evaluation and description of the programme costs; and (3) the evaluation and description of the outcomes.[@R9] Studies were considered 'good quality' when they met all three criteria. Studies that lacked a comparator or had multiple or fatal flaws were determined to be 'poor quality'. All other studies were labelled 'fair quality' if they only contained an evaluation and description of the economic outcomes. In addition, we assessed the risk of bias in the included studies. The included randomised controlled trials (RCTs) were assessed using the Cochrane risk-of-bias criteria.[@R17] The cohort and before-and-after studies were assessed using the Newcastle-Ottawa Scale (NOS), which uses the semiquantisation star system with a full score of 9 stars, and the content evaluated includes the study selection, comparability and outcome. On the NOS, ≥7 stars indicates good quality, 5--7 stars indicates intermediate quality and ≤4 stars indicates poor quality.[@R18]

The heterogeneity of the results prevented a combined statistical analysis, so a qualitative analysis was carried out in this review to classify these articles by the type of CPS, setting and different perspectives, and to analyse the economic impact, existing research status and problems.

Patients and public involvement statement {#s2-5}
-----------------------------------------

Patients and the public were not involved in this study.

Results {#s3}
=======

A total of 2438 relevant papers were obtained from the search, of which 608 were excluded because they were duplicates. Based on the abstracts, 1764 were excluded because they were irrelevant (n=792), did not include an intervention (n=431) or were reviews (n=541). Of the remaining 66 articles, 26 articles were excluded from the review because they evaluated only humanistic or clinical outcomes without an economic assessment. A total of 40 studies met the inclusion criteria for the review. The screening process and results are shown in [figure 1](#F1){ref-type="fig"}.

![Literature search method and screening results.](bmjopen-2019-034862f01){#F1}

Basic characteristics and risk of bias in included studies {#s3-1}
----------------------------------------------------------

The number of studies on this topic has gradually increased since 2010. The study designs were divided into RCTs (n=13), cohort studies (n=16) and before-and-after intervention studies (n=11). Among the included studies, 38 (95%) were conducted in hospitals, while the others were performed in clinics or community pharmacies. The research population mainly focused on adults, and only one study focused entirely on a paediatric population. All of these studies had a concurrent or historical control and were conducted from the perspective of the hospital. Four studies (10%) were deemed to be 'good quality', while the others were described as being 'fair quality' as they only evaluated and described the economic outcomes, such as the drug or hospitalisation cost savings. The characteristics of the 40 included studies are summarised in [table 1](#T1){ref-type="table"}.

###### 

Characteristic of studies eligible for inclusion in this review

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author/year                                                  Study design                  Setting/patients       Simple size (I/C)   Study period                                                  Pharmacist's intervention(s)                                                                                                 Type of economic evaluation    Outcomes measure                                                                  Results                                                                                                                                                                                                                                                                                                                                                                                                                       Quality of economic method
  ------------------------------------------------------------ ----------------------------- ---------------------- ------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ------------------------------ --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Antimicrobial management (type of pharmaceutical services)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Shen *et al* 2011[@R19]                                      Randomised controlled trial   Hospital/adults        354 (176/178)       July 2009--April 2010                                         Pharmacist making recommendations to clinical team of nurses and physicians. Control was absence of pharmacist involvement   Partial economic evaluations   Total costs of hospitalisation and cost of antibiotics                            The total costs of hospitalisation in the intervention group were significantly lower compared with the control group (US\$1442.3±684.9 vs US\$1729.6±773.7). Cost of antibiotics (US\$832.0±373.0 vs US\$943.9±412.0). P\<0.05.                                                                                                                                                                                              Fair

  Yang 2016[@R20]                                              Randomised controlled trial   Hospital/adults        500 (250/250)       September 2013-- September 2015                               Provided DI, pharmaceutical monitoring; advised changes in therapy;                                                          Partial economic evaluations   Cost of antibiotics                                                               The cost of antibiotics in the intervention group was lower compared with the control group (¥177.59±18.11 vs ¥315.33±25.46. P\<0.05.                                                                                                                                                                                                                                                                                         Fair

  Xu 2017[@R21]                                                Randomised controlled trial   Hospital/adults        380 (190/190)       August 2014--August 2016                                      Attended rounds; guided the use of antibiotics and advised changes in therapy                                                Partial economic evaluations   Cost of antibiotics and the proportion of antibiotics in total medical expenses   Antibiotics: intervention group ¥156.82±11.35 versus control group ¥304.27±19.92; the proportion of antibiotics in total medical expenses: intervention group 10.26%±0.21% versus control group 15.26%±00.64%. P\<0.05.                                                                                                                                                                                                       Fair

  He *e* *t al* 2017[@R22]                                     Randomised controlled trial   Hospital/adults        200                 July 2015--July 2016                                          Attended rounds; reviewed sterile operation monitoring to advise antibiotic therapy; provided DI                             Partial economic evaluations   Total costs of hospitalisation and cost of antibiotics                            Antibiotics: intervention group ¥30.53±4.22 versus control group ¥312.43±13.25; total hospitalisation: intervention group ¥5200±43 versus control group ¥7500±102. P\<0.05.                                                                                                                                                                                                                                                   Fair

  Wang 2017[@R23]                                              Randomised controlled trial   Hospital/adults        200 (100/100)       August 2014--August 2015                                      Attended rounds; reviewed prescriptions to advise antibiotic therapy; provided pharmaceutical care                           Partial economic evaluations   Cost of antibiotics                                                               The cost of antibiotics in the intervention group was lower compared with the control group (¥1962.2±261.8 vs ¥2671.8±316.7). P\<0.05.                                                                                                                                                                                                                                                                                        Fair

  Kadier and Tan 2016[@R24]                                    Randomised controlled trial   Hospital/adults        160 (80/80)         June 2014--June 2015                                          Established guidelines for using antibiotics; provided DI, pharmaceutical consultation; attended rounds                      Partial economic evaluations   Cost of antibiotics                                                               The cost of antibiotics in the intervention group was lower compared with the control group (¥134.8±2.89 vs ¥365±23.89). P\<0.05.                                                                                                                                                                                                                                                                                             Fair

  Peng 2017[@R25]                                              Retrospective cohort study    Hospital/adults        800 (400/400)       January 2014--January 2016                                    Provided antibiotic information; reviewed prescriptions; investigated satisfaction of patient                                Partial economic evaluations   Total costs of treatment and cost of antibiotics                                  Total costs of treatment: preintervention ¥2578.16±511.83 versus ¥1919.65±575.14. Cost of antibiotics: preintervention ¥534.25±151.37 versus ¥233.94±149.32. P\<0.05.                                                                                                                                                                                                                                                         Fair

  Cai *et al* 2015[@R26]                                       Retrospective cohort study    Hospital/adults        244 (122/122)       July 2012--September 2012, July 2013--September 2013          Advised antibiotic therapy                                                                                                   Partial economic evaluations   Cost of antibiotics                                                               Antibiotics: preintervention ¥295.34 versus ¥46.41. P\<0.05.                                                                                                                                                                                                                                                                                                                                                                  Fair

  Ren and Pu 2016[@R27]                                        Retrospective cohort study    Hospital/adults        80 (40/40)          March 2015--June 2015, March 2016--June 2016                  Attended rounds; reviewed prescriptions to manage antibiotic therapy                                                         Partial economic evaluations   Total costs of drugs and cost of antibiotics                                      Drugs: preintervention ¥7423±101 versus ¥3674±102. Antibiotics: preintervention ¥2476±245 versus ¥487±243. P\<0.05.                                                                                                                                                                                                                                                                                                           Fair

  Zhang *et al* 2013[@R28]                                     Retrospective cohort study    Hospital/adults        968 (420/548)       January 2009--December 2009, June 2010--May 2011              Reviewed medical records to advise therapy;                                                                                  Partial economic evaluations   Total costs of hospitalisation and cost of antibiotics                            Hospitalisation: preintervention ¥11 265.50 versus ¥8724.70. Antibiotics: preintervention ¥622.60 versus ¥176.19. P\<0.05.                                                                                                                                                                                                                                                                                                    Fair

  Du 2016[@R29]                                                Retrospective cohort study    Hospital/adults        2400 (1200/1200)    2013 and 2014                                                 Attended rounds; reviewed prescriptions to provide DI, and suggestions for alternative therapies                             Partial economic evaluations   Total costs of drugs and cost of antibiotics                                      Drugs: preintervention ¥3742±657 versus ¥2124±465. Antibiotics: preintervention ¥1051±243 versus ¥529±87. P\<0.05.                                                                                                                                                                                                                                                                                                            Fair

  Xu 2016[@R30]                                                Retrospective cohort study    Hospital/adults        2300 (1148/1152)    January 2013--December 2015                                   Attented rounds; guided the use of antibiotics and provided DI; reviewed medical records to advise therapy                   Partial economic evaluations   Cost of antibiotics, total costs of treatment and the ratio                       The cost of antibiotics in the intervention group was significantly lower compared with the control group (¥2037 vs ¥3955). The total costs of treatment (¥5081 vs ¥6379). The ratio (40.7% vs 62.0%). P\<0.05.                                                                                                                                                                                                               Fair

  Lv *et al* 2011[@R31]                                        Retrospective cohort study    Hospital/adults        200 (100/100)       2009 and 2010                                                 Advised changes in therapy                                                                                                   Partial economic evaluations   Cost of antibiotics, medicine and hospitalisation                                 Antibiotics: preintervention ¥423 versus ¥320. Medicine: preintervention ¥1304 versus ¥1018. P\<0.05.\                                                                                                                                                                                                                                                                                                                        Fair
                                                                                                                                                                                                                                                                                                                                                                                                                                                    Hospitalisation: no obvious difference.                                                                                                                                                                                                                                                                                                                                                                                       

  Huang *et al* 2014[@R32]                                     Retrospective cohort study    Hospital/adults        160 (80/80)         2011 and 2012                                                 Provided pharmaceutical monitoring, discharge education, and suggestions for alternative therapies; reported ADR             Partial economic evaluations   Total costs of hospitalisation, drugs, antibiotics and the ratio                  The cost of antibiotics in the intervention group was significantly lower compared with the control group (¥2756.25±653.21 vs ¥4156.25±811.28). Total costs of drugs (¥3105.75±1123.54 vs ¥5489.75±1203.47). Total costs of hospitalisation (¥8213.72±1479.33 vs ¥10 812.65±1756.28). The cost of antibiotics/drugs (33.55%±5.01% vs 38.43±5.16%). The cost of drugs/hospitalisation (37.8%±6.75% vs 50.77±8.78%). P\<0.05.   Fair

  Liu *et al* 2011[@R33]                                       Retrospective cohort study    Hospital/adults        148 (71/77)         September 2009--July 2010                                     Attended rounds, advised antibiotic therapy                                                                                  Partial economic evaluations   Total costs of hospitalisation and drugs                                          Drugs: preintervention ¥1650 versus ¥1162.5, ¥487.5 saved.\                                                                                                                                                                                                                                                                                                                                                                   Fair
                                                                                                                                                                                                                                                                                                                                                                                                                                                    Hospitalisation: preintervention ¥4893.5 versus ¥4059.9, ¥833.6 saved. P\<0.05.                                                                                                                                                                                                                                                                                                                                               

  Hao 2016[@R34]                                               Retrospective cohort study    Hospital/adults        360 (180/180)       January 2013--January 2014, February 2014--February 2015      Provided DI, analysis of drug use                                                                                            Partial economic evaluations   Cost of antibiotics                                                               Antibiotics: preintervention ¥2504.61±314.49 versus ¥1859.09±259.68. P\<0.05.                                                                                                                                                                                                                                                                                                                                                 

  Li and Yang 2014[@R35]                                       Retrospective cohort study    Hospital/adults        2400 (1200/1200)    2009 and 2010                                                 Attended rounds; provided DI, pharmaceutical consultation; reviewed medical records                                          Partial economic evaluations   Total costs of treatment and cost of antibiotics                                  Total costs of treatment: preintervention ¥2576.25±512.47 versus ¥1920.42±576.30. Cost of antibiotics: preintervention ¥533.10±260.55 versus ¥234.50±150.20. P\<0.05.                                                                                                                                                                                                                                                         Fair

  Feng 2014[@R36]                                              Retrospective cohort study    Hospital/adults        4800 (2400/2400)    2011 and 2013                                                 Established guidelines for using antibiotics; provided pharmaceutical consultation; reviewed prescriptions                   Partial economic evaluations   Cost of antibiotics, and the average course of use of antibiotics                 Antibiotics: preintervention ¥542.2±168.3 versus ¥267.4±154.5. Average course: preintervention 4.5±1.1 d versus 3.4±0.9 d. P\<0.05.                                                                                                                                                                                                                                                                                           Fair

  Chu 2016[@R37]                                               Retrospective cohort study    Hospital/adults        336 (168/168)       January 2014--June 2014, July 2014--December 2014             Attended rounds; reviewed medical records to optimise antibiotic therapy; provided pharmaceutical care                       Partial economic evaluations   Total costs of hospitalisation                                                    Hospitalisation: preintervention ¥3105.60±285.20 versus ¥2560.70±229.40. P\<0.05.                                                                                                                                                                                                                                                                                                                                             Fair

  Gan 2016[@R38]                                               Before-and-after study        Hospital/adults        200 (100/100)       2014 and 2015                                                 Attended rounds; reviewed and advised antibiotic therapy                                                                     Partial economic evaluations   Cost of antibiotics                                                               Antibiotics: preintervention ¥6950.50±981.58 versus ¥4208.19±650.04. P\<0.05.                                                                                                                                                                                                                                                                                                                                                 Fair

  Tao and Hu 2014[@R39]                                        Before-and-after study        Hospital/adults        600 (300/300)       2011 and 2012                                                 Attended rounds; provided DI                                                                                                 Partial economic evaluations   Cost of antibiotics                                                               Antibiotics: preintervention ¥1591.4±300.2 versus ¥1102.4±298.5. P\<0.05.                                                                                                                                                                                                                                                                                                                                                     Fair

  Guo 2015[@R40]                                               Before-and-after study        Hospital/adults        2000 (1000/1000)    March 2012--March 2013, June 2013--June 2014                  Established guidelines for using antibiotics; provided DI, pharmaceutical consultation; reviewed medical records             Partial economic evaluations   Total costs of quinolones                                                         Total costs of quinolones: preintervention ¥36.2 thousands versus ¥24.4 thousands.                                                                                                                                                                                                                                                                                                                                            Fair

  Zhou *et al* 2015[@R41]                                      Before-and-after study        Hospital/adults        /                   2010 to 2013                                                  Attended rounds; provided DI; analysed and guided the use of antibiotics                                                     Partial economic evaluations   Total drug cost, antibiotic cost and antibiotic cost percentage                   Comparison of the 2013 data with those of 2010 showed that average antibiotic cost decreased by 246.94 dollars; the cost of antibiotics as a percentage of total drug cost decreased by 27.7%                                                                                                                                                                                                                                 Fair

  Chronic disease state management                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Li *et al* 2011[@R42]                                        Randomised controlled trial   Clinical/adults        150 (79/71)         Not report                                                    Pharmaceutical care (eg, lectures on pharmaceutical, establishment of connection...)                                         Partial economic evaluations   Cost-effectiveness analysis                                                       Intervention group: 684.82±805.97 was better than control group 1376.01±2063.37. P\<0.05.                                                                                                                                                                                                                                                                                                                                     Good

  Chen 2016[@R43]                                              Randomised controlled trial   Hospital/adults        504 (254/250)       July 2015--December 2015                                      Provided DI and suggestions for alternative therapies; prevented ADR                                                         Full economic evaluations      Cost-effectiveness analysis                                                       The observation group cost-effectiveness ratio was significantly lower than the control group (C/E=1627.9 vs 2654.6; p\<0.05); sensitivity analysis (C/E=1557.5 vs 2570.0)                                                                                                                                                                                                                                                    Good

  Huang and Hu 2013[@R44]                                      Randomised controlled trial   Hospital/adults        300 (150/150)       January 2012--December 2012                                   Established guidelines for using antibiotics; attended rounds; provided DI; advised changes in therapy                       Partial economic evaluations   Cost of treatment                                                                 The cost of treatment in the observation group was significantly decreased (¥33.27±9.36 to ¥25.68±7.24; p\<0.05); control group (¥33.29±9.55 to ¥32.74±9.03; p\>0.05)                                                                                                                                                                                                                                                         Fair

  Chen and Su 2016[@R45]                                       Retrospective cohort study    Hospital/adults        80 (40/40)          July 2012--July 2014                                          Provided DI, pharmaceutical monitoring and psychological counselling; guided the use of drugs                                Partial economic evaluations   Cost of treatment                                                                 Cost of treatment: intervention ¥11 274.26±5930.28 versus ¥14173.49±6293.39.P\<0.05.                                                                                                                                                                                                                                                                                                                                          Fair

  Wu *et al* 2016[@R46]                                        Retrospective cohort study    Hospital/adults        420 (262/158)       September 2013--August 2014, September 2014--August 2015      Provided DI (eg, ADR), pharmaceutical monitoring; reviewed medical records to advise therapy                                 Partial economic evaluations   Cost of drugs                                                                     Total costs of drugs: intervention ¥5 581 228.8 versus ¥6 742 349.8. The average cost of drugs: intervention ¥21 302.4 per person versus ¥42 673.1 per person.P\<0.05.                                                                                                                                                                                                                                                        Fair

  Jiang *et al* 2017[@R47]                                     Prospective cohort study      Hospital/adults        124 (63/61)         November 2014--October 2015                                   Attended rounds; provided pharmaceutical care, discharge education; reviewed medical records                                 Partial economic evaluations   Total costs of hospitalisation and drugs                                          The total costs of hospitalisation in the intervention group were significantly lower compared with the control group (¥8537.76±2835.09 vs ¥10 236.28±3043.82). Costs of drugs (¥4275.10±1123.67 vs ¥5339.77±1024.80). P\<0.05.                                                                                                                                                                                               Fair

  Xin *e* *t al* 2013[@R48]                                    Before-and-after study        Hospital/adults        944 (473/471)       January 2012--March 2012, October 2012--December 2012         Attended rounds; reviewed medical records to advise therapy                                                                  Partial economic evaluations   Cost of drugs                                                                     Drug: preintervention US\$347.15 versus US\$309.74. P=0.095.                                                                                                                                                                                                                                                                                                                                                                  Fair

  Xin *e* *t al* 2014[@R49]                                    Before-and-after study        Hospital/adults        849 (429/420)       January 2013--June 2013, July 2013--December 2013             Attended rounds; provided pharmaceutical consultation and monitoring; advised changes in therapy                             Partial economic evaluations   Cost of drugs                                                                     The drug cost per patient day decreased from €254.74 to € 219.85. P=0.095.                                                                                                                                                                                                                                                                                                                                                    Fair

  Long *et al* 2014[@R50]                                      Before-and-after study        Hospital/adults        101                 March 2011--June 2011                                         Provided DI, pharmaceutical consultation and follow-up                                                                       Full economic evaluations      Cost-effectiveness analysis                                                       The cost of pharmacy service: preintervention ¥1899.13 versus ¥1899.13. The C/E: 22.27 versus 21.98                                                                                                                                                                                                                                                                                                                           Good

  Chen and Zhao 2014[@R51]                                     Before-and-after study        Hospital/adults        190                 June 2011--June 2012                                          Provided DI, pharmaceutical consultation and follow-up; guided use of drugs for diabetes                                     Full economic evaluations      Cost-effectiveness analysis                                                       C/E: the ratio of total effect, hypoglycaemic effect, antihypertensive effect and lipid-lowering effect after intervention was 275.4,\                                                                                                                                                                                                                                                                                        Good
                                                                                                                                                                                                                                                                                                                                                                                                                                                    157.0, 240.9 and 184.5 respectively; there was a substantial decline than before the intervention.                                                                                                                                                                                                                                                                                                                            

  Multidimension clinical pharmaceutical services                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Li et al 2015[@R52]                                          Randomised controlled trial   Hospital/adults        120 (60/60)         January 2012--January 2014                                    Optimised therapy; provided pharmaceutical monitoring                                                                        Partial economic evaluations   Total costs of hospitalisation and drugs                                          The cost of drugs in the intervention group was lower than control group (¥3343.2±1833.3 vs ¥3462.1±1929.2). Cost of hospitalisation (¥5117.1±2739.1 vs ¥5234.4±2480.9).P\>0.05.                                                                                                                                                                                                                                              Fair

  Wang 2016[@R53]                                              Randomised controlled trial   Clinical/adults        198 (99/99)         October 2013--January 2016                                    Optimised therapy; provided pharmaceutical monitoring                                                                        Partial economic evaluations   Total costs of hospitalisation                                                    The cost of hospitalisation and the cost of drugs as a percentage of total hospitalisation cost were not statistically significant.                                                                                                                                                                                                                                                                                           Fair

  Qi *e* *t al* 2016[@R54]                                     Randomised controlled trial   Hospital/adults        240 (120/120)       April 2015--April 2016                                        Suggested therapy                                                                                                            Partial economic evaluations   Cost of treatment                                                                 The cost of treatment in the observation group was significantly lower than control group. Saved ¥36.25±2.51 versus ¥1.24±0.03. P\<0.05.                                                                                                                                                                                                                                                                                      Fair

  Han *et al* 2017[@R55]                                       Before-and-after study        Hospital/adults        87 (46/41)          2015 and 2016                                                 Advised therapies of antibiotics, analgesics, adjuvant drugs, antiosteoporotic and anticoagulants                            Partial economic evaluations   Total costs of hospitalisation and drugs                                          Hospitalisation: observation group ¥40 661.82±5489.48 versus ¥46 797.7±4848.61. Drugs: observation group ¥8465.19±2168.54 versus ¥12 290.88±3396.18. P\<0.05.                                                                                                                                                                                                                                                                 Fair

  Liu *et al* 2016[@R56]                                       Before-and-after study        Hospital/adults        173 (92/81)         September 2015--November 2015, December 2015--February 2016   Reviewed prescriptions to suggest therapy adjustments                                                                        Partial economic evaluations   Cost of TPN                                                                       TPN: preintervention ¥1021±218 versus ¥860±176. P\<0.001.                                                                                                                                                                                                                                                                                                                                                                     Fair

  Zhang *et al* 2012[@R57]                                     Randomised controlled trial   Hospital/paediatrics   160 (80/80)         December 2010--March 2011                                     Attended rounds; provided DI, pharmaceutical consultation; reviewed prescriptions to advise therapy                          Partial economic evaluations   Cost of hospitalisation and drugs                                                 Cost of drugs and hospitalisation in the two groups were not statistically different.                                                                                                                                                                                                                                                                                                                                         Fair

  Jiang *et al* 2012[@R58]                                     Before-and-after study        Hospital/adults        825 (416/409)       December 2010--March 2011, March 2011--June 2011              Attended rounds; provided pharmaceutical consultation, ADRM; reviewed medical records to advise therapy                      Partial economic evaluations   Cost of drugs                                                                     Saved US\$40.07/d; the drug cost per patient-day decreased from US\$347.43 to US\$307.36. P=0.095.                                                                                                                                                                                                                                                                                                                            Fair
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ADR, adverse drug reaction; ADRM, adverse drug reaction monitoring; DI, drug information; TPN, total parenteral nutrition.

The results of the assessment of the risk of bias in the RCTs are shown in [table 2](#T2){ref-type="table"}. The bias of risk with regard to the 'blinding of participants and personnel (performance bias)' and the 'blinding of outcome assessment (detection bias)' were high in the included RCTs (because the pharmacist must interact with the patient face to face to provide give drug-use guidance according to each patient's condition). In addition, 'random sequence generation (selection bias)' and 'allocation concealment (selection bias)' had high levels of the risk of bias in almost all the included RCTs; they reported that a randomisation method was employed but do not clearly describe it. The risk-of-bias assessments in the cohort and before-and-after studies showed that 18.5% (n=5) of the studies were 'good quality', while the others (n=22, 81.5%) were 'intermediate quality'. The results of risk-of-bias assessments in the cohort and before-and-after studies are shown in [table 3](#T3){ref-type="table"}.

###### 

Risk of bias for randomised controlled trials

  Study ID                      Random sequence generation (selection bias)   Allocation concealment (selection bias)   Blinding of participants and personnel (performance bias)   Blinding of outcome assessment (detection bias)   Incomplete outcome data addressed (attrition bias)   Selective reporting (reporting bias)   Other bias
  ----------------------------- --------------------------------------------- ----------------------------------------- ----------------------------------------------------------- ------------------------------------------------- ---------------------------------------------------- -------------------------------------- ------------
  Shen *et al* 2011[@R19]       U                                             L                                         H                                                           L                                                 L                                                    L                                      L
  Yang *et al* 2016[@R20]       U                                             U                                         U                                                           U                                                 L                                                    L                                      L
  Xu 2017[@R21]                 L                                             U                                         H                                                           U                                                 L                                                    L                                      L
  He *et al* 2017[@R22]         L                                             L                                         H                                                           U                                                 L                                                    L                                      L
  Wang 2017[@R23]               U                                             L                                         H                                                           U                                                 L                                                    L                                      L
  Kadier and Tan 2016[@R24]     U                                             U                                         H                                                           U                                                 L                                                    U                                      L
  Li *et al* 2011[@R42]         U                                             U                                         U                                                           U                                                 L                                                    L                                      L
  Chen 2016[@R43]               L                                             L                                         H                                                           U                                                 L                                                    L                                      L
  Huang and Hu 2013[@R44]       L                                             U                                         H                                                           U                                                 L                                                    U                                      L
  Li *et al* 2015[@R52]         L                                             L                                         H                                                           U                                                 L                                                    L                                      L
  Wang 2016[@R53]               U                                             U                                         H                                                           U                                                 L                                                    L                                      L
  Qi *e* *t al* 2016[@R54]      L                                             L                                         H                                                           U                                                 L                                                    L                                      L
  Zhang *e* *t al* 2012[@R57]   L                                             L                                         H                                                           L                                                 L                                                    L                                      L

H, high risk;ID, identification; L, low risk; U, unknown.

###### 

Risk of bias for cohort and before-and-after studies

  Study ID                      Selection   Comparability   Outcome   Total number of stars                    
  ----------------------------- ----------- --------------- --------- ----------------------- --- --- --- ---- --------------
  Peng 2017[@R25]               b           a               a         b                       b   b   a   c    ★★★★★★
  Cai *e* *t al* 2015[@R26]     b           a               a         b                       b   b   a   c    **★★★★★★**
  Ren and Pu 2016[@R27]         b           a               a         b                       c   b   a   a    **★★★★★★**
  Zhang *et al* 2013[@R28]      b           a               a         b                       b   b   b   a     **★★★★★★**
  Du 2016[@R29]                 b           a               a         a                       b   b   a    a   **★★★★★★★★**
  Xu 2016[@R30]                 b           a               a         b                       c   b   a   a    **★★★★★★**
  Lv *et al* 2011[@R31]         b           a               a         b                       c   b   a   a     **★★★★★★**
  Huang *et al* 2014[@R32]      b           a               a         b                       b   b   b   a    **★★★★★★**
  Liu *e* *t al* 2011[@R33]     b           a               a         b                       c   b   a   b    **★★★★★★**
  Hao 2016[@R34]                b           a               a         b                       b   b   b   b    **★★★★★★**
  Li and Yang 2014[@R35]        b           a               a         b                       c   b   a   a    **★★★★★★**
  Feng 2014[@R36]               b           a               a         b                       c   b   a   a    **★★★★★★**
  Chu 2016[@R37]                b           a               a         b                       c   b   a   a    **★★★★★★**
  Gan 2016[@R38]                b           a               a         b                       c   b   a   d    **★★★★★**
  Tao and Hu 2014[@R39]         b           a               a         a                       c   b   a   a    **★★★★★★★**
  Guo 2015[@R40]                b           a               a         b                       c   b   a   a    **★★★★★★**
  Zhou *et al* 2015[@R41]       b           a               a         b                       b   b   a   c    **★★★★★★**
  Chen and Su 2016[@R45]        b           a               a         b                       c   b   a   c    **★★★★★**
  Wu *et al* 2016[@R46]         b           a               a         b                       b   b   a   a    **★★★★★★★**
  Jiang *e* *t al* 2017[@R47]   b           a               a         b                       c   b   b   a    **★★★★★**
  Xin *et al* 2013[@R48]        b           a               a         b                       c   b   a   a    **★★★★★★**
  Xin *e* *t al* 2014[@R49]     b           a               a         b                       b   b   a   d    **★★★★★**
  Long *et al* 2014[@R50]       b           a               a         b                       c   b   a   b    **★★★★★★**
  Chen and Zhao 2014[@R51]      b           a               a         b                       b   b   a   a    **★★★★★★★**
  Han *et al* 2017[@R55]        b           a               a         b                       c   b   a   a    **★★★★★★**
  Liu *e* *t al* 2016[@R56]     b           a               a         b                       c   b   a   a    **★★★★★★**
  Jiang *e* *t al* 2012[@R58]   b           a               a         b                       b   b   a   a    **★★★★★★★**

\*a: truly representative of the average (describe) in the community★; b: somewhat representative of the average in the community ★; c: selected group of users, for example, nurses, volunteers; d: no description of the derivation of the cohort.

†a: drawn from the same community as the exposed cohort ★; b: drawn from a different source; c: no description of the derivation of the non-exposed cohort.

‡a: secure record (eg, surgical records)★; b: structured interview ★; c: written self-report; d: no description.

§a: yes ★; b: no.

¶a: study controls for age (select the most important factor) ★; b: study controls for any additional factor (This criteria could be modified to indicate specific control for a second important factor.) c: unclearly, the study no description.

\*\*a: independent blind assessment ★; b: record linkage★; c: self-report; d: no description.

††a: yes (select an adequate follow-up period for outcome of interest) ★; b: no.

‡‡a: complete follow-up---all subjects accounted for ★; b: subjects lost to follow-up unlikely to introduce bias---small number lost follow-up, or description provided of those lost★; c: follow-up rate \<40% (select an adequate %) and no description of those lost; d: no statement.

Clinical pharmacy interventions {#s3-2}
-------------------------------

The type of CPS was classified as one of the three following areas: (1) antimicrobial management services[@R19] (23 (57.5%)) that primarily focused on antimicrobial use and may have included predefined guidelines for the provision of dosing recommendations or the preferred drug; (2) chronic disease state management services[@R42] (10 (25%)) that were primarily directed at patients with a specific disease state or diagnosis, such as a diabetes management programme; and (3) multidimensional clinical pharmaceutical services[@R52] (7 (17.5%)) that encompassed a broad range of activities based on the need of patients. The content of the interventions included the adjustment of dosages; the provision of advice regarding therapeutic drug monitoring; the evaluation of drug history; the provision of drug information to physicians and patients to prevent pharmacological and physicochemical interactions, prescribing and transcription errors and ADEs; the participation in physician rounds; and the implementation and tracking of the use of guidelines regarding the correct use of drugs. In these studies, interventions were generally undertaken by clinical pharmacists and did not involve dispensing services.

Economic impact assessment {#s3-3}
--------------------------

Three studies were full economic evaluations, using the method of cost-effectiveness analysis.[@R43] Others conducted partial economic evaluations that were limited to the direct healthcare costs, estimating the drug and hospitalisation cost savings only. Most studies (97.5%) did not calculate the pharmacist's labour costs. In addition, only two studies (5%) conducted a sensitivity analysis to account for uncertainty in the estimates of the costs and consequences,.[@R43] An incremental cost--benefit ratio or incremental cost-effectiveness ratio (ICER) was presented in one study.[@R50] The transferability of results to other settings or countries was not discussed in all the studies' results.

A positive economic benefit associated with pharmacy services was noted in 80% (n=32) of these studies. The other studies (n=8, 20%) also showed lower medical costs due to pharmacist intervention; however, these trials did not find statistically significant differences in the medication costs saved. In the following discussion, we provide a detailed description of these studies categorised by the type of clinical pharmacy intervention.

### Economic impact of antimicrobial management {#s3-3-1}

Twenty-three studies on CPS included antimicrobial management, and the interventions were conducted in hospitals.[@R19] All of these assessments were partial economic evaluations; among them, 21 studies with a control group applied statistics to compare the two groups, with economic outcomes showing that pharmacists providing antimicrobial management services led to overall cost savings (including the cost of antibacterial drugs, hospitalisation expenses and total treatment costs) in the intervention groups, and the results showed a significant difference (p\<0.05).[@R19] Another two studies also showed that antibiotic costs decreased but were not reported as a statistically significantly different.[@R40]

### Economic impact of chronic disease state management {#s3-3-2}

Ten studies described three disease state management programmes (tuberculosis, diabetes and hypertension).[@R42] Among them, three studies were full economic evaluations, and all of them used cost-effectiveness analyses.[@R43] The pharmacist provision of education to patients with diabetes resulted in a cost-effectiveness ratio (CER) of 21.98 in comparison with the control group (22.27) and the ICER was 21.02, which showed a positive economic outcome based on the estimated cost of providing the service.[@R50] A stewardship programme provided for hypertension was investigated, and the study reported a reduction in the CER (pharmacist present 1627.0 vs no pharmacist 2654.6, p\<0.05) when pharmacists were included as a part of a multidisciplinary team.[@R43] Another study showed a substantial decline in the CER compared with before an intervention occurred (intervention 275. 4 vs no intervention 384. 5), and the CPS improved the effect of the treatment on patients with diabetes mellitus in the community, thereby reducing the cost of treatment.[@R51] Other studies were partial economic evaluations, and they only reported the cost of treatment (including drug charges and hospitalisation expenses), which were reduced after intervention. Service costs were considered in one study,[@R50] but the other studies omitted them.

### Economic impact of multidimensional CPS {#s3-3-3}

There were seven studies on such pharmaceutical services. All of them were partial economic evaluations, which only reported decreased medical costs, and four of the studies showed no statistically significant differences, although medical costs decreased due to pharmaceutical interventions in the results.[@R52] The cost of providing the service was not stated in all studies.

The detailed economic results of each study are shown in [table 1](#T1){ref-type="table"}.

Discussion {#s4}
==========

In this systematic review, a positive economic benefit associated with CPS was noted in 80% (n=32) of the articles, showing that CPS were associated with cost savings. The context of CPS has been expanding from medication dispensing towards providing individualised care in China. The types of services include antimicrobial management, chronic disease state management and multidimensional clinical pharmaceutical services, and the interventions are concentrated in hospitals and community clinics. However, compared with studies from other countries, the types of services provided in China and the settings of the interventions show a lack of diversity. For example, an economic assessment of the CPS in the USA by the ACCP showed that types of CPS also included health screening services, laboratory testing services, wellness programmes, immunisation services and medication therapy management. In addition, studies in the USA evaluated interventions in community settings, clinics, long-term monitoring institutions, rehabilitation organisations and so on.[@R3] Faced with China's current healthcare reform, increasing numbers of hospitals are paying more attention to the development of CPS with the hope that pharmacists can provide more correct guidance regarding drug use, thereby saving medical resources. By expanding the breadth of CPS, further economic savings could be garnered; however, the evaluation of services in other settings, such as the community, will be needed to determine if similar savings are obtained.

CPS are still in the early stages of development in China, and the number of studies on the economic evaluation of pharmaceutical services has only gradually increased since 2010. Most of the included studies focused on adults. Among the included studies, 80% reported a positive economic benefit associated with CPS, but only four (10%) of the studies were 'good quality'. Most of the studies were partial economic evaluations that cited clinical effects as the main outcome, and the economic outcome was added as an afterthought; these studies only reported direct cost savings, for example, hospitalisation and drug-related cost savings. In addition, these studies did not calculate hidden costs and potential savings; only one study took into account the pharmacist's labour costs and time input. When input costs are not appropriately estimated, it leads to the overestimation of the cost savings, rendering it impossible to make an informed decision regarding the true value of CPS. Future economic evaluations should pay more attention to paediatric populations and conduct full economic evaluations in which all relevant direct healthcare costs and the indirect costs of productivity loss are considered and measured, including pharmacist employment costs.

CPS have existed in China for more than 20 years, and there is a vast body of original research about the economic impact of pharmacy services. However, to the best of our knowledge, the present study is the first to systematically review the economic evaluation literature on CPS in China. The results of this study showed that CPS have resulted in beneficial outcomes for patients, such as reducing drug costs, the length of stay and the cost of treatment; in addition, one pilot programme showed that nearly all directors of hospitals, doctors, pharmacy directors and patients surveyed (n=207) supported the role of clinical pharmacists.[@R59] However, whether and how to 'pay pharmacists for patient care' is still an area of debate. Our research provides information that can be used by healthcare administrators regarding the potential return on investment afforded by CPS. This information can help guide those responsible for allocating medical resources when faced with reforms of the healthcare system and skyrocketing healthcare costs. This work further highlights the gaps in knowledge where further research is needed, forming the foundation for designing future economic evaluations of pharmacy interventions in the region.

This review has some limitations. First, in the process of study selection, some grey articles were unavailable and not included in this review. Second, this study might be affected by publication bias, as negative or non-significant results may have remained unpublished. Third, the literature search was conducted until January 2018; next, we will update the literature review every 3 years. Fourth, the included studies were conducted in different hospitals, with different kinds of patient and various interventions, making it difficult to compare the results and preventing the performance of a meta-analysis. Therefore, we qualitatively analysed the results. In addition, most included studies were partial economic evaluations and had a risk of bias. Among the included RCTs, 46.2% (n=6) had selection bias (random sequence generation and allocation concealment). Many articles reported that they used randomisation methods; however, some of them did not clearly report the randomisation approach, which may reduce the credibility of the evaluation findings. Furthermore, sensitivity analyses were not considered in many studies because the changes in parameter values could result in different results and conclusions. All cohort studies used retrospective experimental designs with the recommended methods for collecting and reporting economic information. Future studies should adopt full economic evaluations in which all relevant costs and outcomes are considered and measured. Furthermore, efforts should be made to improve the quality of the studies to decrease the risk of bias. All guidelines available regarding the design and reporting of economic evaluations should be used by authors when developing the economic portion of their studies.[@R60]

Conclusion {#s5}
==========

Clinical pharmacy interventions are associated with cost savings. However, most studies had limitations in their methodological quality and applicability to current practice. Compared with CPS and the evaluations of CPS in other countries, the types of pharmaceutical services in China were limited, and most studies adopted partial economic evaluations. It is suggested that new pharmaceutical services be included in future studies and that full economic evaluations capturing both expenses and cost savings be conducted to promote the development of pharmaceutical care.
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